Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

Wave Life Sciences recently reported positive interim Phase 1 INLIGHT trial data for its RNA obesity candidate WVE-007, showing single-dose reductions in visceral and total body fat alongside ...

Access detailed historical stock prices, including daily closing prices, for QBTS. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...

Wave Life Sciences shares jumped in premarket trading Monday after it said it received encouraging preliminary trial data for its investigational weight loss drug WVE-007. Shares advanced nearly 78% ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...

Wave Life Sciences Ltd. (NASDAQ: WVE) on Monday shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE ...

Editor's note: This article was updated at 430p to reflect Monday's closing gain. Wave Life Sciences (WVE) closed Monday up ~147% after reporting that a single 240 mg dose of its experimental obesity ...

The AI boom has sparked a construction frenzy — and the scale of financing needed is only just starting to hit the public eye. "Tip of the iceberg. It's just beginning," John Cortese, head of ...

CAMBRIDGE, Mass. - Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of approximately $1.25 billion, will release interim data from its Phase 1 ...

Elite universities like Harvard, Princeton and Columbia spend fortunes on research, talent and digital infrastructure. Even then, they've become easy targets for attackers who see massive databases ...